Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down
02:25pm, Tuesday, 29'th Apr 2025
REGN reports lower-than-expected Q1 results. Lead drug Eylea sales plunge in the United States due to competition.
Regeneron Pharmaceuticals, Inc. (REGN) Q1 2025 Earnings Call Transcript
12:30pm, Tuesday, 29'th Apr 2025
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ET Company Participants Ryan Crowe - SVP, IR Leonard Schleifer - Board Co-Chair, Co-Founder, Pres
Top Stock Movers Now: Honeywell, Sherwin-Williams, Regeneron, and More
12:06pm, Tuesday, 29'th Apr 2025
U.S. equities were higher at midday as markets waited for further clarification from the Trump administration about possible changes in tariff policy. The Dow Jones Industrial Average rose 0.6%, and t
Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say
10:35am, Tuesday, 29'th Apr 2025
The headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estima
Regeneron Stock Plummets After Earnings Miss
09:11am, Tuesday, 29'th Apr 2025
First-quarter adjusted earnings per share were $8.22 on revenue of $3 billion, missing analysts' expectations of EPS of $8.62 on revenue of $3.2 billion, according to FactSet.
Regeneron (REGN) Lags Q1 Earnings and Revenue Estimates
08:40am, Tuesday, 29'th Apr 2025
Regeneron (REGN) came out with quarterly earnings of $8.22 per share, missing the Zacks Consensus Estimate of $8.43 per share. This compares to earnings of $9.55 per share a year ago.
Regeneron Pharma's first-quarter results miss on lower Eylea demand
08:28am, Tuesday, 29'th Apr 2025
Regeneron missed Wall Street estimates for first-quarter results on Tuesday, hurt by waning demand for its blockbuster eye disease drug Eylea, sending the company's shares tumbling 7% in premarket tra
BMO's Evan Seigerman breaks down Pfizer and Regeneron's Q1 results
08:11am, Tuesday, 29'th Apr 2025
Evan David Seigerman, BMO head of healthcare research, joins 'Squawk Box' to break down Pfizer and Regeneron's quarter earnings results.
Regeneron Reports First Quarter 2025 Financial and Operating Results
06:30am, Tuesday, 29'th Apr 2025
TARRYTOWN, N.Y., April 29, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2025 and provided a business update.
Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts?
01:11pm, Monday, 28'th Apr 2025
Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their first-quarter 2025 results later this week.
Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma
07:01am, Monday, 28'th Apr 2025
Approval of Lynozyfic is based on data showing deep and durable responses in relapsed/refractory multiple myeloma Lynozyfic will provide a new option with convenient dosing and administration to pati
Market Sell-Off: 2 Stocks Down 17% and 36% This Year to Buy and Hold
09:30am, Saturday, 26'th Apr 2025
What should investors do during a stock-market correction? One great strategy is to go shopping.
What Analyst Projections for Key Metrics Reveal About Regeneron (REGN) Q1 Earnings
10:21am, Thursday, 24'th Apr 2025
Besides Wall Street's top -and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the
Regeneron to Report Q1 Earnings: What's in Store for the Stock?
03:30pm, Tuesday, 22'nd Apr 2025
Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports first-quarter results on April 29.
Regeneron Expands US Manufacturing With $3 Billion Fujifilm Deal
01:12pm, Tuesday, 22'nd Apr 2025
Regeneron Pharmaceuticals, Inc. REGN on Tuesday announced a significant expansion of its manufacturing capacity through a new agreement with FUJIFILM Diosynth Biotechnologies to manufacture and supp
